Comparative Pharmacology
Head-to-head clinical analysis: HC 1 versus PANDEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC 1 versus PANDEL.
HC #1 vs PANDEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown
Pandel (hydrocortisone probutate) is a topical corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins inhibit the release of arachidonic acid from membrane phospholipids, thereby reducing the synthesis of prostaglandins, leukotrienes, and other inflammatory mediators. This results in vasoconstriction, decreased edema, and suppression of the inflammatory and pruritic responses.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
Topical: Apply a thin film to affected skin areas twice daily. Maximum: 15 g per application; not to exceed 60 g per week.
None Documented
None Documented
2–4 hours (terminal); prolonged in renal impairment.
2-4 hours (terminal); clinical context: requires frequent dosing due to rapid elimination.
Renal: 90% as unchanged drug; fecal: 10%.
Primarily renal (90% as unchanged drug); biliary/fecal excretion negligible (<5%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid